Shares of Eli Lilly LLY climbed about 4% on Monday after the drugmaker unveiled encouraging new clinical data for its next-generation obesity treatment, retatrutide.
This has reinforced investor confidence in the company’s long-term position in the rapidly expanding weight-loss market.
The latest results were presented at the American Diabetes Association’s annual Scientific Sessions in New Orleans, where Lilly released full data from two late-stage retatrutide studies involving treatment-naive type 2 diabetes patients and individuals living with obesity.
The stock outperformed rival Novo Nordisk, whose US-listed shares declined during the session despite announcing that prescriptions for its oral weight-loss therapy Wegovy had surpassed 3 million since its January launch.
Wall Street appeared to favor Lilly’s expanding clinical pipeline over Novo’s commercial momentum, highlighting the growing competition between the two pharmaceutical giants that dominate the GLP-1 obesity market.
Retatrutide data strengthens Lilly’s obesity portfolio
Investors focused particularly on the performance of retatrutide’s 4 mg dose, which delivered approximately 19% weight loss in clinical testing.
According to analysts, the result is broadly comparable to the highest dose of Lilly’s blockbuster obesity therapy Zepbound.
The lower dose also demonstrated favorable tolerability, with treatment discontinuation rates and instances of vomiting remaining relatively low, although side effects increased at higher doses.
“The 4mg dose efficacy data for retatrutide are compelling enough that first-line positioning cannot be dismissed,” Citi analysts wrote in a note. They added that the treatment could become “the next step for patients who have exhausted Lilly’s tirzepatide efficacy.”
Lilly also highlighted additional findings showing that retatrutide produced meaningful improvements in knee osteoarthritis pain and sleep apnea alongside substantial weight loss.
The company further presented data on its oral obesity treatment Foundayo, previously known as orforglipron.
Lilly said the pill was associated with significant weight loss in women across every stage of menopause based on analyses from its Phase 3 ATTAIN-1 and ATTAIN-2 clinical trials.
Novo Nordisk highlights commercial success
While Lilly showcased the breadth of its development pipeline, Novo Nordisk emphasized the commercial progress of its oral Wegovy therapy.
The company said US prescriptions for the treatment have exceeded 3 million since its launch in early January, describing it as one of the largest pharmaceutical launches in US history.
Goldman Sachs analyst Asad Haider acknowledged Novo’s early advantage after bringing oral Wegovy to market three months ahead of Lilly’s Foundayo.
“The Wegovy pill achieved instant popularity, making it ‘one of the best launches we’ve seen in pharmaceuticals — and it didn’t come at the expense of injectables,'” Haider said.
Even so, the analyst believes Lilly holds important long-term advantages.
“Our view remains that Lilly is going to continue to dominate the GLP-1 market across both existing therapies — oral and injectables — as well as next-generation,” Haider said.
He added: “We think it’s going to be hard for [Novo] to scale over the years to meet that international demand, whereas Lilly can.”
Analysts see Lilly extending its market leadership
Several analysts argued that Lilly’s broader obesity portfolio gives it a growing competitive edge.
J.P. Morgan analyst Chris Schott said, “LLY has the pieces in place to further raise the standard of care in the obesity space, and we see the company if anything further extending its leadership position in the $200 billion+ incretin/obesity market longer term.”
Citi Research analyst Geoff Meacham also maintained a positive outlook following the ADA conference.
“The company’s incretin portfolio is not built around singular blockbusters,” Meacham wrote.
In his view, orforglipron and retatrutide “carry development programs with enough indication breadth to make them category-defining franchises.”
Meacham also highlighted Lilly’s experimental obesity therapy eloralintide, saying the drug “adds a genuinely differentiated layer” to the company’s portfolio, with Phase 2 data suggesting potentially best-in-class efficacy and tolerability.
RBC Capital Markets analyst Trung Huynh echoed that view, saying the depth of Lilly’s obesity portfolio “highlighted its leadership growing rather than a narrowing gap with competitors”.
The post Eli Lilly stock rises as Retatrutide data boosts obesity drug lead appeared first on Invezz
